3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
2
Status
Unknown
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
21
Other solid neoplasm
4
Thoracic
3
Head & Neck
3
Gynecologic
3
Other hematologic neoplasm
2
Gastrointestinal
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Melanoma
2
Neoplasm Metastasis
1
Interventions
pembrolizumab
81
Nivolumab
55
Ipilimumab
44
Cyclophosphamide
37
aldesleukin
26
Interleukin-2
25
Temozolomide
17
fludarabine
16
fludarabine phosphate
15
trametinib
11
dabrafenib
11
Radiotherapy
11
Biopsy
11
avelumab
10
Paclitaxel
9
spartalizumab
8
cemiplimab
8
Dacarbazine
8
Cisplatin
8
Bevacizumab
8
sargramostim
7
binimetinib
7
Fluorouracil
7
poly ICLC
6
lenvatinib
6
epacadostat
6
atezolizumab
6
Magnetic Resonance Spectroscopy
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
montanide ISA 51
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
palbociclib
×
Dermatologic
×
Clear all
NCT04720768
2024-01-05
CELEBRATE
Peter MacCallum Cancer Centre, Australia
Phase 1/2
Unknown
78 enrolled
NCT02202200
2016-04-18
OPTIMUM
Assistance Publique - Hôpitaux de Paris
Phase 1/2
Unknown
40 enrolled